CORTES SALINAS, LINA JIMENA
Preferred name
CORTES SALINAS, LINA JIMENA
Main Affiliation
Email
lcortes@udd.cl
ORCID
0000-0001-8119-5417
Scopus Author ID
57452456900
15 results
Now showing 1 - 10 of 15
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antibiotic use in Chilean salmon aquaculture: antimicrobial resistance, sustainability, and One Health implications(Frontiers Media SA, 2026-05-08); 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multicenter Study to Determine the Immune Response to the Vaccine Against SARS COV-2, in Patients With Chronic Kidney Disease on Dialysis and Kidney Transplants(2022); ; ; 1 - Some of the metrics are blocked by yourconsent settings
Item type:Product, 10 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Overcoming Health Inequities: Spatial Analysis of Seroprevalence and Vaccination Against COVID-19 in Chile(2024); Scopus© Citations 1 6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile(2022); ; ; <jats:p>Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.</jats:p>6Scopus© Citations 12 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group(2022)23Scopus© Citations 19 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Deep immunophenotyping reveals biomarkers of multisystemic inflammatory syndrome in children in a Latin American cohort(2022); ; Scopus© Citations 16 8 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Population-based seroprevalence survey: post-pandemic COVID-19 vaccination, related factors, and geographic distribution of vaccine acceptability in Chile(Springer Science and Business Media LLC, 2025-03-28); ; 10 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes<jats:p>Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.</jats:p>Scopus© Citations 3 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients(2023); ; ; 8Scopus© Citations 5